It is difficult for clinicians to stay current with the evolving treatment options for colorectal cancer, and they can benefit from education about these therapies.

Clinicians must be trained to use assessment tools and stay abreast of the trial data that are available to improve morbidity and mortality in those over 60 or 65. Pharmacists have the opportunity now to improve treatment outcomes and communication between patient and provider, so the patient receives the best care for their situation and goals.

Being familiar with the current management of breast cancer will help clinicians support their patients and to communicate with specialists in the multidisciplinary team.

Clinicians should regularly evaluate recent clinical trial data to make informed decisions on the most appropriate treatment plan, particularly as new targeted therapies, as well as new indications for existing targeted therapies, become FDA-approved.

The biomarker-driven treatment of non-small cell lung cancer is evolving rapidly and pharmacists should be aware of new data, therapies, and treatment recommendations in order to support the multidisciplinary health care team and provide optimal patient care.

Pharmacists should be aware of the new data and recommendations surrounding novel agents and how they relate to improvements in patient survival and quality of life. It is also important to be aware of the potential for unique and potentially severe adverse events that can occur with these therapies.

Education on the appropriate use of newly approved therapies and considerations for treatment planning and side effect management can benefit clinicians interested in incorporating these therapies into their clinical practice.

Adjuvant treatment options for patients with advanced renal cell carcinoma (RCC) following surgery are continually evolving, and new treatment options for different stages of RCC are being approved. It can be challenging for clinicians to remain up-to-date on these updates.

Clinical trials are continuing to investigate the role of induction chemotherapy prior to systemic therapy/radiation therapy for patients with locoregionally advanced nasopharyngeal carcinoma. New evidence regarding the addition of a PD-1 inhibitor to gemcitabine/cisplatin provides an emerging avenue of treatment for patients with recurrent or metastatic disease. It is important for clinicians to remain current on emerging treatment options for patients with nasopharyngeal carcinoma.

Pharmacists play a critical role in patient education, monitoring, and management of treatment-related toxicities and would benefit from a comprehensive review of the novel treatments for indolent non-Hodgkin lymphomas.